Glen Burkhardt Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Burkhardt PHAS stock SEC Form 4 insiders trading

Glen has made over 4 trades of the PhaseBio Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 11,248 units of PHAS stock worth $8,886 on 20 May 2022.

The largest trade he's ever made was selling 11,248 units of PhaseBio Pharmaceuticals stock on 20 May 2022 worth over $8,886. On average, Glen trades about 3,475 units every 78 days since 2020.

You can see the complete history of Mr. Burkhardt stock trades at the bottom of the page.

Glen Burkhardt biography

Glen G. Burkhardt serves as Vice President - Human Resources of the Company. Prior to joining our company, Mr. Burkhardt served as vice president of human resources for Hologic, Inc. from June 2014 to October 2018. He received a B.S. and a B.Arch. from Ball State University and an M.B.A. from the Kelley School of Business at Indiana University.

How old is Glen Burkhardt?

Glen Burkhardt is 61, he's been the Vice President - Human Resources of PhaseBio Pharmaceuticals since 2019. There are 3 older and 14 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.

What's Glen Burkhardt's mailing address?

Glen's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.

Insiders trading at PhaseBio Pharmaceuticals

Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... és Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.

What does PhaseBio Pharmaceuticals do?

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Complete history of Mr. Burkhardt stock trades at PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals executives and stock owners

PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jonathan Mow,
  Chief Executive Officer, Director
• Jonathan P. Mow,
  Pres, CEO & Director
• John Lee,
  Chief Medical Officer
• John Sharp,
  Chief Financial Officer
• Dr. John S. Lee,
  Chief Medical Officer
• John P. Sharp,
  Chief Financial Officer
• Clay Thorp,
  Co-Founder, Independent Chairman of the Board
• Peter Klein,
  Independent Director
• Nancy Hutson,
  Independent Director
• Richard van den Broek,
  Independent Director
• Caroline Loewy,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Alex Sapir,
  Independent Director
• Michael York,
  Vice President - Corporate Development and Commercial Strategy
• Jim Ballance,
  Vice President - Research and Scientific Affairs
• Susan Arnold,
  Vice President - Preclinical and Chemistry, Manufacturing and Controls
• Kristophe Hanson,
  Vice President - Head of Legal, Corporate Secretary
• Glen Burkhardt,
  Vice President - Human Resources
• Jonathan J. Birchall,
  Chief Commercial Officer
• Glen Burkhardt,
  VP of HR
• Lauren Richardson,
  Global Head of Regulatory Affairs & Quality Assurance
• Kristopher L. Hanson,
  VP, Head of Legal & Corp. Sec.
• Bibhash Mukhopadhyay,
  Director
• David James Ballance,
  VP, Research and Sci. Affairs
• Linda Tufts,
  Director
• William D. Humphries,
  Director
• Jonathan Birchall,
  Chief Commercial Officer
• Enterprise Associates 13 Lp...,